CL-197 vs Doravirine/islatravir (Idvynso)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
CL-197
Developed by Henan Genuine Biotech
NCT05944848 · Phase 1 · completed
The study randomly assigned healthy volunteers to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, it tested only safety and drug levels in healthy volunteers rather than any HIV outcome, and results have not been posted. Its registered primary outcome on ClinicalTrials.gov is "The Safety and Tolerability of CL-197 Capsules :Incidence of Treatment-Emergent Adverse Events as Assessed by The NCI CTCAE V5.0 Grading Criteria". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07308782 (registry estimate)
No aligned efficacy figure on record for this race.
Doravirine/islatravir (Idvynso)
Marketed by Merck & Co.
NCT05631093 · Phase 3 · active, not recruiting
Trial 051 randomized 551 virologically suppressed adults with HIV-1 2:1, open-label, to switch to once-daily doravirine/islatravir or stay on their baseline antiretroviral regimen. The primary efficacy endpoint was the proportion with HIV-1 RNA at or above 50 copies/mL at Week 48, tested for non-inferiority with a 4-percentage-point margin. The rate was 1.4% after the switch and 4.9% on baseline therapy (difference -3.58, 95% CI -7.81 to -0.77), so non-inferiority was shown and the primary endpoint was met. The other registered primaries are adverse-event rates. Source: ClinicalTrials.gov posted results and the IDVYNSO US label, section 14.
Next expected readout: May 2029 · NCT04776252 (registry estimate)
Reported efficacy
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48; Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48; Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). (met)
Result source: NCT05630755
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | CL-197 | Doravirine/islatravir (Idvynso) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Trial running · NCT05630755 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Trial running · NCT05630755 |
| CD4 count, change (week 48) | —Not reported | —Trial running · NCT05630755 |
HIV-1 RNA below 50 copies/mL (week 48)
- CL-197
- —Not reported
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
HIV-1 RNA 50 copies/mL or more (week 48)
- CL-197
- —Not reported
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
CD4 count, change (week 48)
- CL-197
- —Not reported
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
CL-197: no structured comparison results are available for HIV.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CL-197's landscape · Doravirine/islatravir (Idvynso)'s landscape